YORK PHARMA PLC – Product Pipeline Review – Q1 2011
Global Market Direct’s pharmaceuticals report, “YORK PHARMA PLC - Product Pipeline Review - Q1 2011” provides data on the YORK PHARMA PLC’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, YORK PHARMA PLC’s corporate website, SEC filings, investor presentations and featured press releases, both from YORK PHARMA PLC and industry-specific third party sources, put together by Global Markets Direct’s team.
- YORK PHARMA PLC - Brief YORK PHARMA PLC overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of YORK PHARMA PLC human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of YORK PHARMA PLC with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the YORK PHARMA PLC’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate YORK PHARMA PLC’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of YORK PHARMA PLC in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the YORK PHARMA PLC’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows
YORK PHARMA PLC – Product Pipeline Review – Q1 2011 Reference Code: GMDHC1272CDB Publication Date: JUN 2011 YORK PHARMA PLC – Product Pipeline Review – Q1 2011 GMDHC1272CDB / Published JUN 2011 © Global Markets Direct. This report is a licensed product and is not to be photocopied Page(1) YORK PHARMA PLC – Product Pipeline Review Ta b le o f Co n te n ts Table of Contents 2 List of Tables 3 List of Figures 3 YORK PHARMA PLC Snapshot 4 YORK PHARMA PLC Overview 4 Key Information 4 Key Facts 4 YORK PHARMA PLC – Research and Development Overview 5 Key Therapeutic Areas 5 YORK PHARMA PLC – Pipeline Review 7 Pipeline Products by Stage of Development 7 Pipeline Products – Monotherapy 8 YORK PHARMA PLC – Pipeline Products Glance 9 YORK PHARMA PLC Clinical Stage Pipeline Products 9 Phase II Products/Combination Treatment Modalities 9 YORK PHARMA PLC–Early Stage Pipeline Products 10 Pre-Clinical Products/Combination Treatment Modalities 10 YORK PHARMA PLC – Drug Profiles 11 Vampex 11 Product Description 11 Mechanism of Action 11 R&D Progress 11 RPL228 12 Product Description 12 Mechanism of Action 12 R&D Progress 12 YORK PHARMA PLC – Pipeline Analysis 13 YORK PHARMA PLC – Pipeline Products by Therapeutic Class 13 YORK PHARMA PLC - Pipeline Products By Target 14 YORK PHARMA PLC – Pipeline Products by Route of Administration 15 YORK PHARMA PLC – Pipeline Products by Molecule Type 16 YORK PHARMA PLC - Dormant Projects 17 YORK PHARMA PLC – Locations And Subsidiaries 18 Head Office 18 Financial Deals Landscape 18 YORK PHARMA PLC, Deals Summary, 2004 to 2011 18 YORK PHARMA PLC Detailed Deal Summary 19 Acquisition 19 RH Acquisitions Acquires York Pharma 19 York Pharma Acquires Molecular SkinCare From Interleukin Genetics 20 ULURU Terminates Acquisition Of York Pharma 22 Appendix 23 Methodology 23 Coverage 23 Secondary Research 23 Primary Research 23 YORK PHARMA PLC – Product Pipeline Review – Q1 2011 GMDHC1272CDB / Publishe
Pages to are hidden for
"YORK PHARMA PLC – Product Pipeline Review – Q1 2011"Please download to view full document